Postoperative adjuvant chemotherapy is not recommended for stage 1b invasive lung adenocarcinoma if it is completely surgically resected, while postoperative adjuvant chemotherapy can be considered for those with high risk factors. 1. For stage 1b invasive lung adenocarcinoma with complete surgical resection, postoperative adjuvant chemotherapy, radiotherapy and targeted therapy are not recommended at present. 2. However, postoperative adjuvant chemotherapy is needed for stage 1b invasive lung adenocarcinoma with high-risk factors, which include: poorly differentiated, neuroendocrine carcinoma (except well-differentiated neuroendocrine carcinoma), vascular invasion, wedge resection, tumors larger than 4 cm, involvement of the pleura of the visceral layer and inadequate lymph node dissection. As this disease is highly specialized, one should go to regular hospitals in time, determine specific treatment plan under the guidance of doctors, and actively cooperate with the treatment to avoid deterioration of the condition.